Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients

@inproceedings{AlJurdi2022DiminishedAR,
  title={Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients},
  author={Ayman Al Jurdi and Rodrigo Benedetti Gassen and Thiago de Jesus Borges and I. Tadeval Lape and Luisa Morena and Orhan Efe and Zhabiz Solhjou and Rania El Fekih and Carlos Deb{\'a}n and Brigid Bohan and Vikram Pattanayak and Camille Nelson Kotton and Jacques Azzi and Leonardo V. Riella},
  booktitle={medRxiv},
  year={2022}
}
Abstract: Background: Available SARS-CoV-2 vaccines have reduced efficacy against the Omicron variant in immunocompetent individuals. Kidney transplant recipients (KTRs) have diminished antiviral responses to wild-type SARS-CoV-2 after vaccination, and data on antiviral responses to SARS-CoV-2 variants, including the Omicron variant, are limited. Methods: We conducted a prospective, multi-center cohort study of 51 adult KTRs who received three doses of BNT162b2 or mRNA-1273. Blood and urine… 
Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron
TLDR
It is indicated that prior infection and vaccination can induce highly protective antibody responses in many SOTRs, and important factors (shorter time since transplantation, prednisone administration, and African American ethnicity) that limit these responses are identified.
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
TLDR
Current knowledge on the immunobiology of SARS-COV-2 mRNA vaccination in animal models and in healthy humans is reviewed and the first data on third dose mRNA vaccine administration in immunocompromised patients are reviewed.

References

SHOWING 1-10 OF 32 REFERENCES
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients In contrast to immunocompetent participants in vaccine trials,1,2 a low proportion (17%) of solid organ
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.
TLDR
Data indicated that immunosuppression resulted in impaired protective immunity after mRNA vaccination, including Ig induction with corresponding generation of plasmablasts and memory B cells, Thus, there is an urgent need to improve vaccination protocols in patients after kidney transplantation or on chronic dialysis.
Reduced humoral response to mRNA SARS‐CoV‐2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
  • A. Grupper, L. Rabinowich, H. Katchman
  • Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2021
TLDR
The findings suggest that most kidney transplant recipients remain at high risk for COVID‐19 despite vaccination, and further studies regarding possible measures to increase recipient's response to vaccination are required.
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.
TLDR
The antibody responses of kidney transplant recipients who did not respond to 2 doses and received a third dose of the mRNA-1273 (Moderna) vaccine were examined.
Cellular and humoral response after mRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients
  • D. Cucchiari, Natalia Egri, F. Diekmann
  • Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2021
TLDR
It is concluded that mRNA‐1273 SARS‐CoV‐2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.
Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
TLDR
In SOTRs undergoing mRNA vaccination, reactogenicity was similar to that reported in the original trials and these early safety data may help address vaccine hesitancy in transplant recipients.
Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
TLDR
There was a substantial fall in neutralisation titres in recipients of both AZD1222 and BNT162b2 primary courses, with evidence of some recipients failing to neutralise at all, which will likely lead to increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection.
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
TLDR
Blood samples taken soon after vaccination from individuals who were vaccinated and previously infected with SARS-CoV-2 or vaccinated with no evidence of previous infection support the notion that reasonable protection against Omicron may be maintained using vaccination approaches.
SARS‐CoV‐2 Omicron variant: Characteristics and prevention
TLDR
The Omicron variant harbors a high number of mutations, including 15 mutations in the receptor‐binding domain (RBD) of spike, which immediately raised global concerns about viral transmissibility, pathogenicity, and immune evasion.
Plasma Neutralization of the SARS-CoV-2 Omicron Variant
...
...